Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Cybin Inc.
< Previous
1
2
3
4
5
6
7
8
Next >
CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program
August 08, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights
August 08, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference
July 28, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Date of Annual Meeting of Shareholders
July 25, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
July 11, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
June 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
June 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
June 22, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
June 16, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
June 09, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Acquires DMT Clinical Study from Entheon Biomedical
June 07, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievements
June 03, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
June 03, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy
June 02, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Host Key Opinion Leader Webinar on June 9, 2022
June 02, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022
May 17, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022
May 11, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality’ Global Summit on Psychedelic-Assisted Therapies and Medicine
May 05, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022
April 22, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
April 21, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT
April 13, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
April 08, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the Benzinga Psychedelics Capital Conference in Miami on April 19, 2022
April 06, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
April 01, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
March 31, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
March 29, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
March 25, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants
March 24, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022
March 16, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
February 18, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.